Lv1
40 积分 2021-10-26 加入
Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond
10天前
已关闭
Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedema—Prevalence and Relevance
11天前
已完结
The OX40-OX40L Co-stimulatory pathway in dermatology: emerging frontiers for therapeutic approaches
18天前
已完结
Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real‐life study
2个月前
已完结
Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients
2个月前
已完结
Dupilumab as a novel therapy for bullous pemphigoid
2个月前
已完结
62452 Bullous pemphigoid treated with dupilumab. Retrospective study in a Spanish third-level hospital
2个月前
已关闭
The treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors with biologic therapy: A single-institution retrospective study at a tertiary care cancer center
2个月前
已完结
Serum inflammatory biomarkers associated with disease severity and response to dupilumab treatment in bullous pemphigoid: a cluster analysis
2个月前
已完结
Dupilumab as a Therapeutic Option in Autoimmune Bullous Diseases Following SARS‐CoV‐2 Infection and COVID‐19 Vaccination: A Comprehensive Case Series Analysis
3个月前
已完结
皖公网安备34019202002308
